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Background: Myoblasts and stem cells implanted into myocardium can differentiate
into myocytes and may functionally improve impaired ventricles. For implanted
cells to actually contribute to the synchronous contractions of the heart, however,
they must be anatomically integrated with the existing native myocardial fibers.
Methods: Isogenic Lewis rats were used as donors and recipients to simulate clinical
autotransplantation. Either skeletal myoblasts or marrow stromal stem cells were
isolated from donors, culture expanded, and labeled with 4,6-diamidino-2-
phenylindole (4,6-diamidino-2-phenylindole). Labeled cells were then injected into
the myocardium of recipients. At intervals specimens were obtained, sectioned, and
stained with hematoxylin and eosin and immunohistochemically against con-
nexin-43 to demonstrate gap junctions (intercalated discs).
Results: At 1 week the labeled cells were still undifferentiated, but early expression
of connexin-43 could be detected at contact points between the implanted cells and
the native myocytes. By 4 to 6 weeks, labeled, fully differentiated myocytes could
be seen to interconnect among themselves and with native cardiomyocytes by means
of intercalated discs. In sections parallel to the myofibers, full integration of new
labeled myocytes with the native myofiber cells could be observed. Furthermore, the
labeled myofibers were in parallel with the native, unlabeled fibers. We postulate
that such supracellular structural integration was enhanced by fiber stretching during
cardiac contractions, sending signals for cellular reorientation and incorporation, in
which the cytoskeletal system may play an important role.
Conclusion: We conclude that implanted precursor cells can be integrated into
native myocardial structure so as to contribute to myocardial function. Direct
cell-to-cell contact seems to be an important signaling mechanism, which has
implications for cellular implantation strategies.
The aim of cell replacement therapy for heart failure is to replacecardiomyocytes irreversibly lost to necrosis and apoptosis. Variousdonor cell sources have been studied, including fetal cardiomyo-cytes,1 myoblasts,2-7 and embryonic and adult stem cells.8-10Use of autologous myoblasts (satellite cells)6 and marrow stromalstem cells (MSCs)9 has clinical advantages, because these cells are
readily available for every patient and their use does not require immunosuppres-
sion. Our earlier studies and those of others have confirmed that these cells are able
to survive and undergo myogenic differentiation on implantation into myocardi-
um.11 Although the ultimate phenotypic expression of implanted skeletal myoblasts
remains controversial at this time,4 there is strong evidence that MSCs can be
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induced to express a cardiomyocytic phenotype, both in
vitro8 and in vivo.9 Such differentiation of MSCs, which are
now known to be pluripotent stem cells residing in the bone
marrow of both immature and mature subjects, has been
investigated and elucidated at molecular and cellular lev-
els.12 To achieve the clinical goal of using these cells to
provide new contractile muscle capable of assisting the
ventricular function of a failing heart, however, we need
additional evidence that such cells can in fact be incorpo-
rated and integrated into the supracellular anatomic archi-
tecture of the myocardium.
Unlike other striated muscles, the myocardium is
uniquely structured to achieve synchronous, all-or-none
contractions in response to a depolarizing electric signal.
Thus the cardiomyocytes are interconnected by specialized
cell-cell junctions, histologically known as intercalated
discs, to form syncytial fibers. These fiber bundles13 are
arranged in complex layers of circular, oblique, and longi-
tudinal orientations to form the ventricular wall, optimized
to perform its physiologic functions. This report explores
the feasibility of supracellular integration of the neocardio-
myocytes and myofibers derived from the implanted myo-
blasts and stem cells by extending and reappraising the
observations made in our recent studies.6,9 On the basis of
these findings and the existing information on cellular
mechanotransduction and cytoskeletal function,14 we fur-
ther propose a mechanistic hypothesis as to how such inte-
gration may take place, thus providing an anatomic basis for




Isogenic male Lewis rats weighing 200 to 250 g (Charles River
Laboratories, Laprairie, Quebec, Canada) were used as donors and
recipients to simulate clinical autologous implants. Animals re-
ceived humane care in compliance with the “Guide to the Care and
Use of Experimental Animals” of the Canadian Council on Animal
Care.
Isolation and Culture of Skeletal Myoblast Cells
After overdose with pentobarbital, the skeletal muscles of both
hind quarters of adult rats were excised. As described previously,6
the muscle was rinsed with 70% ethanol and then with 15 mL
Hanks balanced salt solution (Life Technologies, Inc, Rockville,
Md). It was then minced with scissors. After addition of 50 mL
Hanks balanced salt solution, muscle fragments were sedimented
at 2000 rpm for 2 minutes. The supernatant was discarded. The
specimen was then incubated in 100 mL of 1% collagenase (Sig-
ma, St Louis, Mo) and 0.2% type 1-S hyaluronidase in M199 (Life
Technologies), supplemented with 5000-U/mL penicillin and
5000-g/mL streptomycin (Life Technologies), for 60 minutes at
37°C in a shaker bath. Remaining muscle mass was then spun at
2000 rpm for 2 minutes. The sedimented muscle fragments were
then incubated with 50 mL of 1% pronase solution (Sigma) for 30
minutes at 37°C to release myogenic cells. Fetal bovine serum
(Life Technologies) was added to the total supernatant to halt
further enzymatic cleavage processes. Isolated myoblast cells were
plated on 60 mm polystyrene tissue culture dishes. (Corning In-
corporated, Corning, NY) at a density of 1  106 cells per culture
dish. Growth medium, each 100 mL composed of 82 mL of M199,
7.4 mL of minimal essential medium (Sigma), 10 mL of fetal
bovine serum, 5000 U/mL penicillin, 5000 g/mL of streptomy-
cin, 250 L of amphotericin B, and 40 L of gentamicin, was
replaced every 24 to 48 hours. Culture dishes seeded with myo-
genic cells were maintained in a 37°C humidified atmosphere
(95% air with 5% carbon dioxide) and passaged every 48 hours.
Myoblasts were subjected to a 30-second period of treatment with
trypsin (Life Technologies) diluted 10 times in M199 to facilitate
detachment of cells from the tissue culture dishes.
Isolation and Culture of MSCs
Isolation and primary culture of MSCs were performed according
to the method of Caplan.15 As described before,9 MSCs were
isolated from the femoral and tibial bones of donor rats. These
cells in 10 mL of complete medium were then introduced into
tissue culture dishes. Medium was completely replaced every 3
days, and the nonadherent cells were discarded. To prevent the
MSCs from differentiating or slowing their rate of division, each
primary culture was replated (first passaged) to three new plates
when the cell density within colonies became 80% to 90% con-
fluent, approximately 2 weeks after seeding. After the twice-
passaged cells became nearly confluent, they were harvested, la-
beled with 4,6-diamidino-2-phenylindole (DAPI),16 and used for
the implantation experiments described here. The cells were cul-
tured in complete medium consisting of Dulbecco modified Eagle
medium containing selected lots of 10% fetal calf serum and
antibiotics (100-U/mL penicillin G, 100-g/mL streptomycin, and
0.25-g/mL amphotericin B; Life Technologies) at 37°C in a
humidified atmosphere with 5% carbon dioxide.
Skeletal Myoblast and MSC Labeling
Sterile DAPI solution was added to the culture medium on the day
of implantation at final concentrations of 200 g/mL for myoblasts
and 50 g/mL for MSCs. The dye was allowed to remain in the
culture dishes for 30 minutes. The cells (either myoblasts or
MSCs) were rinsed 6 times in Hanks balanced salt solution to
remove all excess, unbound DAPI. Myoblasts and MSCs were
collected (approximately 1  106 cells for each implantation) and
resuspended in minimal volume of serum-free Dulbecco modified
Eagle medium. At this point they were ready for implantation into
the myocardium.
Skeletal Myoblast and MSC Implantation
Isogenic male Lewis rats weighing 200 to 250 g served as the
recipients of the donor cells. Anesthesia was induced, the animal
was intubated, and a left lateral thoracotomy was performed in the
fourth intercostal space. Under direct vision, 1  106 labeled cells
(skeletal myoblasts or MSCs) were injected into the left ventricular
wall with a 28-gauge needle. An 8-0 Prolene suture (Ethicon Ltd,
Peterborough, Ontario, Canada) was used to mark the injection
track. The thoracotomy was closed, and the animal was returned to
the animal care facility.
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The rats were taken for their final experiments at the following
intervals after the implantation: 1 week (n  4 rats), 4 weeks (n 
4 rats), and 6 weeks (n  6 rats). After overdose with pentobar-
bital, the hearts were exposed and injected with 100 mL saline
solution (0.9%) through the posterior wall of the left ventricle,
avoiding the transplanted area, then cryoembedded after protection
with 20% sucrose in phosphate-buffered saline solution or embed-
ded in paraffin after being perfusion fixed with 2% paraformalde-
hyde in phosphate-buffered saline solution.
Histologic and Immunohistochemical Examinations
The lateral wall of left ventricle was isolated from the remainder of
the heart. Frozen and paraffin sections 6 m in thickness were
collected across a set of glass slides to ensure that different stains
could be carried out on successive sections of tissue cut through
the implantation area. One of the sections was mounted without
stain for location of the DAPI-labeled donor cells under a fluores-
cence microscope. A successive section was stained with hema-
toxylin and eosin to depict nuclei, cytoplasm, and connective
tissue. Other sections were selected for immunostaining of con-
nexin-43 with rabbit polyclonal antibody (Zymed Laboratories Inc,
South San Francisco, Calif). Sections were incubated in primary
antibodies overnight at 4°C. Detection used secondary anti-
connexin-43 antibodies conjugated with fluorescein. Combined
DAPI and fluorescein images were made with simultaneous exci-
tation filter under a reflected light fluorescence microscope (BX-
FLA; Olympus America Inc, Melville, NY). Digital images, trans-
ferred to a computer equipped with Image Pro software (Media
Cybernetics, LP, Silver Spring, Md), were subsequently printed.
Results
The labeling efficiency of cultured myoblasts and MSCs
with DAPI approached 100% (Figure 1, A and D, respec-
tively). The operative mortality in our series was less than
5%.
In the myoblast implantation series, the implanted fluo-
rescent myoblasts appeared elongated 1 week after implan-
tation (Figure 1, B). Four weeks after implantation, the
implanted myoblasts formed DAPI-positive myofibers.
Conspicuously, these fibers were not randomly oriented.
The labeled myofibers had aligned themselves in parallel
with each other and with unlabeled native cardiac myofibers
(Figure 1, C).
In the MSC implantation series, at 6 weeks the cells in
the cardiac myofibers clearly expressed connexin-43 along
the axial junctions between DAPI-labeled (implanted) cells
and neighboring unlabeled cells (native cardiomyocytes;
Figure 1, E). The implanted cells had changed shape,
aligned in parallel to the native cardiomyocytes (Figure 1,
F, top), and fully integrated into the cardiac myofibers. In
fact, these cardiac myofibers containing new labeled cardi-
omyocytes appeared completely normal under hematoxylin
and eosin staining (Figure 1, F, bottom).
Discussion
Electromechanical coupling of myocardial cells is necessary
for the myocardial syncytium to contract as a unit. Myocar-
dial cells are connected by specialized cell-cell junctions,
the intercalated discs, which allow electrical and mechani-
cal continuity among cells. Intercalated discs consist of gap
junctions (connexin-43 is the major gap junction protein17
responsible for electrical coupling), fascia adherens junc-
tions (N-cadherin18 is the major protein responsible for
mechanical coupling), and desmosomes. Hexamers of con-
nexin-43 allow exchange of ions and small molecules across
the membranes of adjacent cells. Recently, Reinecke and
associates19 reported electromechanical coupling between
cardiomyocytes cocultured with skeletal myotubes. They
demonstrated expression of cadherin and connexin-43 at
junctions between cultured myotubes and cardiomyocytes.
The junctions formed were responsible for electrical stim-
ulation and contraction of myotubes. These skeletal myo-
tube-cardiomyocyte junctions transferred calcium and dye
across the membranes. These junctional proteins appeared
to be downwardly regulated after intramyocardial implan-
tation, although the reason for this was not clear. However,
Robinson and colleagues20 showed in vivo that C2C12
myoblasts engrafted into murine hearts after arterial injec-
tion formed intercellular connections similar in ultrastruc-
ture to gap junctions. These junctions were rich in connexin-
43, fascia adherens, and desmosomes, signifying
electromechanical coupling of adjoining C2C12-native
myocardial cells.
On the basis of our findings and the data reported by
these other investigators,19,20 we propose the hypothesis that
implanted cells express specific proteins to form gap junc-
tions on contacting the host myocardium. These cell-cell
junctions allow the implanted cells to communicate electri-
cally with the rest of the myocardial syncytium and expose
the implants to mechanical stretch of cardiac contraction
generated by the adjacent cells. We posit that such mechan-
ical signals cause implanted cells to alter their shape, mi-
grate,14 and integrate into existing myofibers (Figure 2). The
orientation of new myofibers is guided by the vector of the
contractions of adjacent fibers, such that they also align in
parallel with other fibers in that particular layer of the
myocardium.14
Mechanical force has been shown to function as an
environmental cue to trigger phenotypic changes in many
cell types, such as vascular smooth muscle and endothelial
cells. For example, Kanda and Matsuda21 demonstrated that
exposure of cultured smooth muscle cells to periodic stretch
induced alignment of cells parallel to the direction of stretch
and increased the abundance of myofilaments. Wilson and
associates22 have suggested that mechanical strain is sensed
by integrins and specific matrix proteins in vascular smooth
muscle. Such understandings of the capability of cells for
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Figure 1. A, Cultured skeletal myoblasts stained with DAPI (blue fluorescence). Note that virtually 100% of cultured
cells are labeled.6 B, Labeled cells within host myocardium 1 week after myoblast implantation. Note undiffer-
entiated appearance of cells.6 C, Labeled myoblasts 4 weeks after implantation have developed into labeled
myofibers. Note that these new fibers are in parallel with adjacent native, nonfluorescent cardiac myofibers. D,
Cultured MSCs stained with DAPI (blue fluorescence). Note that virtually 100% of cultured cells are labeled. E,
Connexin-43 expression of MSCs in specimen 6 weeks after implantation. Combined DAPI (blue fluorescence) and
connexin-43 (green fluorescence) image. Anti-connexin-43 immunofluorescence is elicited by using fluorescein-
conjugated secondary antibody. Positive connexin-43 staining (arrows) is found at interface between DAPI-labeled
cells (arrowheads) and neighboring unlabeled cells. F, Top, DAPI-labeled cells are aligned and structurally
integrated into native cardiomyofibers; native cardiomyocytes in these fibers are not labeled. Bottom, consecutive
section stained with hematoxylin and eosin. Note that implanted cells are indistinguishable from native cells.
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autoassembly form the basis for culturing cells in a “bio-
reactor”23 that reproduces mechanical pulsation in vitro for
tissue engineering of artificial arteries. In this sense the
integration in the myocardium can be seen as an autoassem-
bly of the implanted cells, with the contractile native myo-
cardium serving as an in vivo bio-reactor, providing the
signals needed for the supracellular incorporation that we
observed.
Endothelial cells exposed to steady flow likewise realign
themselves in the direction of flow, a process driven by
reorganization of the cytoskeleton, as demonstrated both in
vitro24and in vivo.25 In response to mechanical strain, actin
microfilaments reorganize themselves from a banding pat-
tern around the periphery of the cell to a series of long,
parallel fibers along the long axis of the aligned cell. Cy-
toskeletal components F-actin and vimentin-rich intermedi-
ate filaments both connect to membrane proteins (integrins)
and undergo alignment with unidirectional flow. Thus the
mechanical force sensed by the extracellular matrix is trans-
mitted intracellularly by integrins to the cytoskeleton, which
leads to a cellular morphologic change. Although specific
data in this regard are lacking for cardiomyocytes, we
suspect a similar mechanism is involved. The mechanical
stress of myocardial contraction is transmitted by the cy-
toskeleton to the nucleus of the implanted cell, which leads
to migration, changes in the cellular shape, and integration
with the existing myofibers (Figure 1, F). The parallel
alignment of new myofibers, as seen in Figure 1, C, can also
be orchestrated by the reorganization and function of the
cellular cytoskeletal system.
From this viewpoint, it is rather perplexing that myo-
blasts and MSCs implanted within a myocardial scar have
been reported to be able to contribute to the diastolic and
systolic functions of the hearts. In these studies the cells
were injected into the center of a scar caused by cryoinjury
or coronary artery ligation. Although these cells seemed to
undergo myogenic differentiation, they did not appear to
connect and integrate with native cardiac fibers and were
without evidence of gap junction formation. How such cells
can contribute to systolic function and improve systolic
work index7 is not clear. Some data obtained with an iso-
volumic Langendorff preparation may be questioned, be-
cause the investigators used resting ventricular balloon vol-
umes to represent preloads in constructing a Frank-Starling
curve, despite the fact the cardiac sizes were significantly
different between their comparison groups.10 The hearts that
received cell implants seem to be smaller than control
hearts, perhaps because of reduced scar expansion and ven-
tricular remodeling. Curiously, even implantation of smooth
muscle cells has been reported to reduce cardiac dilata-
tion.26 Such observations have led to the suggestion that
presence of such cells within the scar changes the physical
property of the scar tissue, exerting a shielding effect to
reduce scar expansion.11 This explanation, however, may
not be consistent with a report that cell implantation in fact
improved diastolic compliance of the scar tissue, as mea-
sured with ultrasonic microcrystals placed across the scar
tissue.7 Thus there remains uncertainty regarding the reli-
ability and mechanisms of putative improvement in cardiac
function after cell implantation inside myocardial scars.
Study Limitations
In this kind of study, the technique of cell labeling used is
of paramount importance, because it is crucial for differen-
tiating myocytes derived from the implanted cells from
those of the native myocardium. Although DAPI, used in
this study for cell labeling, had been used and reported on
by earlier investigators,27,28 there were some concerns re-
garding its specificity, because the labeled cells might re-
lease DAPI molecules on their death after implantation, and
leaked DAPI could then label the native myocytes in vivo to
give false-positive results. Our own validation study to
exclude this possibility has previously been published.6 We
tested the worst case scenario by directly injecting DAPI
into the myocardium, and we confirmed that even with
massive doses relative to that which might leak out from
dead cells, DAPI failed to stain any native cells in vivo. We
postulate that this is due to the rapid washout of free DAPI
molecules in vivo, because the established labeling protocol
in vitro requires incubation of these cells with DAPI for 30
to 60 minutes. Thus the limitation of using DAPI is not its
possible false-positive results, but rather the risk of false-
negative results if the implanted cells had divided and
multiplied many times before terminal differentiation. If
this were the case, the progeny cells might not be labeled,
giving false-negative results that could affect the quantita-
Figure 2. Schematic scenario of integration of neocardiomyocyte
into native cardiac myofiber. See text for explanations.
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tive results. We did not attempt quantitative analysis of our
data, which was a limitation of this study.
The major advantages of DAPI relative to other tech-
niques are that its labeling efficiency is virtually 100% and
it is not toxic to the cells. It is also known that DAPI has
greatest affinity to bind the regions of DNA rich in adenine-
thymine pairs, but in high concentrations it can also bind to
tubulin and microtubules in the cytoplasm.29 Because in our
myoblast implant experiments we used 200 g/mL of
DAPI, both the nuclei and cytoplasm were stained (Figure
1, B and C). For the MSC experiments, however, the DAPI
used was 50 g/mL, and thus only the nuclei were fluores-
cent (Figure 1, E and F). The discrepancy in the DAPI
concentrations used is a reflection of our refinement in the
labeling technique as we studied MSCs after our earlier
experience with the myoblasts. This limitation does not
affect the validity of our findings. Further investigations,
such as correlating our observations with ultrastructures and
functional data, are desirable in future studies.
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Discussion
Dr Alain Carpentier (Paris, France). I enjoyed this presen-
tation, particularly the investigation of whether muscular cells are
more appropriate for this type of cellular cardiomyoplasty. The
ultimate goal of cellular cardiomyoplasty is to enhance contractil-
ity of the myocardium. To do so, you must demonstrate not only
the survival of the implanted cells but also the transformation of
the metabolism of these cells from glycolytic metabolism to oxi-
dative metabolism. Were you able to determine that by using a
specific antibody, and what did you find?
Dr Chedrawy. We have not actually looked at the metabolic
aspects of cellular cardiomyoplasty. The study focused solely on
the structural aspects, in hopes of providing an anatomic basis for
the functional improvements that have been described. I agree that
this is something to be looked into in further investigations.
Sir Magdi Yacoub (London, United Kingdom). I enjoyed your
presentation. I have several questions. First, did you select your
stem cells by flow cytometry or selecting lin negative, for exam-
ple? Second, when you looked at the cells, did you look for
cardiomyocyte-specific transcription factors, such as MIF-2 or
GATA-4? For these myocytes or myogenic cells to function,
especially if they are derived from bone marrow, they should have
cardiac-specific sarcomeric proteins. Did you find, for example,
troponin I or other myocardial-specific sarcomeric isoforms, be-
cause that would be essential? Finally, what do you think is the
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origin of your connexin-43? Is it from the native cardiomyocytes
or from the transplanted cells?
Dr Chedrawy. With respect to the first question, the MSCs
were isolated according to the method of Caplan, in which the
marrow was harvested from the long bones of the rats, the cells
were plated on a culture dish, and the supernatant was discarded.
All the cells that adhered to the culture dish, which is the distin-
guishing property of these cells, were used for the MSC implan-
tation.
With respect to your second question, we did not actually look
at MIF-2 as a transcription factor. We looked strictly at the
implantation process and the anatomic structural integration.
With respect to your third question, we did look at cardiac-
specific contractile proteins. In our case, sarcomeric myosin heavy
chain protein was expressed by these implanted MSCs. We did not
look at troponin I in particular.
With respect to your fourth question regarding connexin-43
expression, I am not really sure whether the MSCs themselves
would express connexin-43. However, we know from in vitro
studies by Dr Charles Murray’s group that coculture of skeletal
myotubes with cardiac cells leads to coexpression of connexin-43.
So perhaps some similar mechanism is operating in this case,
although I do not know for sure.
Dr Robert C. Robbins (Stanford, Calif). I believe that the title
of your article is a bit misleading. These really are not stem cells,
or at least you have not proved that they are stem cells. I probably
missed it, but did you create any ischemia or any injury to the
myocardium?
Dr Chedrawy. With respect to your first point, about calling
the MSCs stem cells, the pluripotent nature of these MSCs is being
elucidated on a monthly basis, and more and more tissues of
mesenchymal, ectodermal, and neurodermal origin are being har-
vested from these stem cells. That is why we refer to them as stem
cells and not as mesenchymal tissue origin cells.
With respect to your second concern, we actually injected all
these cells into normal myocardium. We wanted to expose these
cells to the normal cardiac milieu in the event that they would
undergo a milieu-dependent differentiation and transform into
cardiomyocytes.
Dr Robbins. I have two quick follow-up questions. First, do
you have any scanning electron microscopy to further delineate the
ultrastructure? Second, what do you think about your cells in an
ischemic model, such as cryoinjury or ligation of a coronary artery?
Dr Chedrawy. With respect to your first question, scanning
electron microscopy was not included as part of the study. How-
ever, I agree that it would definitely be of value to clarify the
ultrastructure of these cells, especially the cell-to-cell junctions.
With respect to your second question, we have implanted these
cells in ischemic models, both cryoinjury and coronary ligation.
However, our biggest concern was the actual survival of these cells
within the myocardially induced scar.
Dr Robbins. And did they survive?
Dr Chedrawy. As long as 2 weeks.
Dr Richard D. Weisel (Toronto, Ontario, Canada). What do
you think happens in the ischemic model?
Dr Chedrawy. I think that the biggest concern with the isch-
emic model is that they are not receiving that stimulus to actually
convert into myocardial cells because they are not exposed to the
normal environmental cues in the myocardium.
Dr Weisel. To what do they convert?
Dr Chedrawy. Various forms of fibroblasts.
Dr Weisel. So maybe that is not the right answer for infarct
replacement.
Dr Joseph B. Shrager (Philadelphia, Pa). In terms of showing
differentiation toward cardiac muscle, if you are going to use
expression of a myosin heavy chain to try to establish this, you
have to use something other than generic sarcomeric myosin heavy
chain. The  cardiac myosin heavy chain is the only one that is
found only in cardiac muscle. Any of the other isoforms of myosin
heavy chain are found in skeletal muscle, and therefore their
presence does not establish cardiac differentiation.
Dr Chedrawy. We did not look at an  myosin heavy chain.
We strictly looked at sarcomeric myosin heavy chain. However,
you are right, we could have stained for other cardiac-specific
proteins.
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